⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28855716 | 0.84 | — | — | |
| SCHEMBL888469 | 0.84 | — | — | |
| SCHEMBL6630034 | 0.80 | — | — | |
| SCHEMBL28455739 | 0.76 | — | — | |
| SCHEMBL24520168 | 0.75 | — | — | |
| SCHEMBL1986240 | 0.75 | — | — | |
| SCHEMBL13009095 | 0.75 | — | — | |
| SCHEMBL416473 | 0.75 | — | — | |
| SCHEMBL21573215 | 0.75 | — | — | |
| SCHEMBL10175367 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997651-B | Novel tetrazole compounds and their use in the treatment of tuberculosis | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-01-03 | — | — | CN | disclosed |
| US-11072591-B2 | Tetrazole compounds and their use in the treatment of tuberculosis | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-27 | — | — | US | disclosed |
| US-11072591-B2 | Tetrazole compounds and their use in the treatment of tuberculosis | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-27 | — | — | US | disclosed |
| EP-3668856-B1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| US-20200231555-A1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-23 | — | — | US | disclosed |
| US-20200231555-A1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-23 | — | — | US | disclosed |
| EP-3668856-A1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| CN-110997651-A | Novel tetrazole compounds and their use in the treatment of tuberculosis | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019034729-A1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034729-A1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| US-20130029970-A1 | CB Receptor Agonists | IRONWOOD PHARMACEUTICALS, INC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029970-A1 | CB Receptor Agonists | IRONWOOD PHARMACEUTICALS, INC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029970-A1 | CB Receptor Agonists | IRONWOOD PHARMACEUTICALS, INC (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011006066-A1 | CB RECEPTOR AGONISTS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011006066-A1 | CB RECEPTOR AGONISTS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |